share_log

华东医药：利拉鲁肽注射液糖尿病适应症及肥胖或超重适应症均有望在今年获批上市

Huadong Pharmaceutical: Liraglutide injections for diabetes indications and those for obesity or overweight are all expected to be approved for marketing this year

Breakings ·  02/22 09:14
Huadong Pharmaceutical said on the interactive platform that the company's pioneering ADC drug HDM2002 (IMGN853) for the treatment of platinum-resistant ovarian cancer and HDM3001 (QX001S), a biosimilar drug of ussenumab (Stelara, Sidano) for treating moderate to severe plaque psoriasis in adults, are expected to submit BLA in China this year; the fluorescence tracer MB-102 injection used in conjunction with the MediBeacon glomerular filtration rate dynamic monitoring system is expected to submit an application for marketing this year; the company's mevatinib tablets are currently being marketed Phase III clinical trials have been conducted, and it is expected that marketing applications will be submitted this year; liraglutide injections for diabetes indications and those for obesity or overweight are all expected to be approved for marketing this year.

This page is machine-translated. Futubull tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.


Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

    Write first comment